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Background: There has been a few data about the long-term clinical outcomes of
patients with coronary artery aneurysm (CAA) after drug-eluting stent (DES) im-
plantation. The aim of study is to explore the long-term clinical outcomes of CAA
after DES implantation.
Methods: A total of 94 patients with CAA (105 lesions) after DES implantation (CAA
group) were retrospectively compared with 523 patients (523 lesions) who underwent
DES implantation (non-CAA group). The primary end point was deﬁned as major
adverse cardiac events (MACE) : composites of all-cause death, non-fatal myocardial
infarction (MI), or target vessel revascularization (TVR). Propensity score-matching
analysis was performed in 85 patient pairs.
Results: CAA group had higher incidence of hypertension (64.9% vs. 53.2%,
p¼0.03), lower incidence of dyslipidemia (55.3% vs. 67.2%, p¼0.02), andB28 JACC Vol 64/11/Suppl B j Septemblonger duration of dual antiplatelet therapy (1323860day vs. 767636day,
p< 0.01). Procedural data showed that CAA group had more 1st generation DES
(95.2% vs. 51.4%, p< 0.01), lower stent size (3.000.33mm vs. 3.190.44mm,
p< 0.01) and longer stent length (38.218.5mm vs. 31.717.6mm, p< 0.01).
During a median follow-up period of 860802 days, CAA group had signiﬁ-
cantly higher incidence of MACE (34.0% vs. 7.7%, p< 0.01), which was mainly
driven by non-fatal MI (13.8% vs. 0.76%, p< 0.01) and TVR (28.7% vs. 1.53%,
p< 0.01). The incidence of stent thrombosis was also higher in CAA group
(10.64% vs. 0.19%, p< 0.01). Cox proportional hazard analysis demonstrated
that independent predictors for MACE were CAA (hazard ratio [HR]: 2.53,
[95% conﬁdence interval (CI): 1.528-4.186]), stent number (HR: 1.62, 95% CI:
1.002-2.626), and the prior coronary artery bypass (HR: 4.84, 95% CI: 1.464-
16.029). After propensity-score matching, CAA group still had signiﬁcantly
higher incidence of MACE (32.9% vs. 5.8%, p< 0.01), non-fatal MI (14.1% vs.
0%, p< 0.01), TVR (27% vs. 1.2%, p< 0.01), and stent thrombosis (10.6% vs.
0%, p< 0.01).
Conclusions: CAA group had worse long-term clinical outcomes than non-CAA
group, especially by increase of stent thrombosis, non-fatal MI or TVR. Indeﬁnite use
of DAPT may be needed for CAA patients.
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Background: Elevations of cardiac troponin (cTn) over the upper reference limit
(URL) is a well known predictor of adverse prognosis in unstable coronary artery
disease (CAD). Novel more sensitive cTn assays have the potential for stratifying cTn
levels within the normal range also in patients with apparently stable CAD. The aim of
our study was to evaluate the prognostic value of preprocedural cTnI levels below the
URL, measured with a contemporary available sensitive assay, in stable CAD patients
treated with percutaneous coronary interventions (PCI).
Methods: In 1063 consecutive patients with normal baseline cTnI levels treated with
elective and angiographically successful PCI, we investigated the correlation between
pre-PCI cTnI levels and major clinical adverse events (median follow up of 3.0 years).
Results: Preprocedural cTnI levels were stratiﬁed into tertiles. When compared with
the lower, the upper tertile showed an increased long term risk of overall death (HR
3.17, 95% CI 1.62 to 6.21; P¼0.0001), cardiac death (HR 5.09, 95% CI 2.30 to 11.25;
P¼0.002), myocardial infarction (MI) (HR 2.34, 95% CI 1.45 to 3.76; P¼0.003) and
target vessel failure (TVF) (HR 1.91, 95% CI 1.28 to 2.84; P¼0.006). After adjust-
ment for clinical and angiographic ﬁndings, baseline cTnI level remained an inde-
pendent predictor of cardiac death, MI and TVF.
Conclusions: In a large single-centre population of stable CAD patients treated with
successful PCI, pre-procedural cTnI level, even if below the URL, resulted a strong
independent predictor of long term hard end points.
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Background: Beta-blocker therapy has been shown to beneﬁt in patients presenting
with acute coronary syndrome or left ventricular (LV) dysfunction. However, whether
beta-blockers provide a similar beneﬁt in stable coronary artery disease (SCAD) pa-
tients with normal LV function after percutaneous coronary intervention (PCI) is
unknown.
Methods: A population of 4,266 patients with SCAD with normal LV function who
were treated by PCI was evaluated. Among those, beta-blocker was prescribed in 2794
(65.5%) patients. Primary endpoint was the composite of death from any cause and
spontaneous myocardial infarction (MI).
Results: During the mean follow-up of 31.510.4 months, primary endpoint of
the composite of death and MI were occurred in 97 (3.5%) patients with beta-
blocker and 62 (4.2%) patients without beta-blocker, respectively. Unadjusted
hazard ratio (HR) for the primary end-points was 0.819 (95% CI 0.595 to 1.126,
p¼0.219); for death, 0.724 (95% CI, 0.510 to 1.028, p¼0.071); for MI, 1.136
(95% CI, 0.573 to 2.251, p¼0.700). After adjusting baseline characteristics,
adjusted HR was 0.802 (95% CI 0.577 to 1.116, p¼0.191) for the primary-
endpoint; 0.729 (95% CI 0.507 to 1.047, p¼0.087) for death; 1.124 (95% CI
0.562 to 2.248, p¼0.741) for MI.
Conclusions: In SCAD patients with normal LV function after PCI, beta-blocker was
not associated with signiﬁcant reduction of death or MI.er 13–17, 2014 j TCT Abstracts/Angioplasty Overview and Outcomes
